Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
November 01, 2022 09:05 ET
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
November 01, 2022 06:02 ET
|
Jeito Capital
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
March 16, 2022 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
Jeito Capital co-leads $65 million Series A financing in EyeBio
February 22, 2022 05:01 ET
|
Jeito Capital
Jeito Capital co-leads $65 million Series A financing in EyeBio EyeBio is a newly launched global company developing the next generation of eye disease therapiesFounded by two pioneers in...
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics
November 29, 2021 00:05 ET
|
Jeito Capital
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for...
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)
September 20, 2021 01:00 ET
|
Jeito Capital
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round
June 15, 2021 01:00 ET
|
Jeito Capital
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
May 27, 2021 02:00 ET
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
December 14, 2020 01:00 ET
|
Jeito Capital
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito’s third international investment in H2 2020, with deep and rapidly...